Project Grant R01HL183635
- Federal Grant Award Summary Rutgers The State University of New Jersey, RBHS-School of Nursing, received a $249,000 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded July 21, 2025, with a completion date of June 30, 2028. The grant supports research to identify novel epigenetic regulators of lymphocyte development with applications to T cell immunotherapy. The project will utilize induced...
- Federal Project Grant Award Summary Rutgers The State University of New Jersey (RBHS-School of Nursing) received a $117,750 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2026, through February 28, 2028. The award funds research to identify the biological mechanisms underlying stroke and neurocognitive impairment in adults with sickle cell disease (SCD), which affects over 120,000...
- Federal Project Grant Award Summary Rutgers The State University of New Jersey, School of Nursing received a $316,992 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 27, 2025, with completion targeted for June 26, 2029. The grant supports basic research investigating the developmental role of the second heart field (SHF), a mesodermal progenitor population, in the formation of lymphovenous...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Rutgers The State University of New Jersey a $721,720 Project Grant effective September 1, 2025, through July 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative investigates the psychosocial and cultural determinants of cardiometabolic health among older foreign-born Chinese Americans, an understudied population disproportionately affected by...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $688,163 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding May 31, 2029. This research grant supports an investigator-initiated project examining indole metabolites as xenobiotic danger signals in acute lung injury. The principal investigator, a physician in pulmonary and critical care medicine at the...
- Federal Grant Award Summary Rutgers, The State University received a $235,500 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2027. The award funds research to uncover cross-disease platelet transcriptomic signatures that advance precision medicine across cardiovascular, immune-mediated, cancer, and hematologic diseases, including myeloproliferative neoplasms....
- Federal Grant Award Summary Pennsylvania State University, operating through Penn State Milton S. Hershey Medical Center, received a $105,705 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026, through December 31, 2027. The award supports fundamental biomedical research investigating the molecular mechanisms by which surfactant protein-A (SP-A) and its genetic variants...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Research Foundation For The State University of New York (RF SUNY), operating as Upstate Medical Center, a $448,250 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger ribonucleic acid (mRNA)-lipid nanoparticle system for treating acute respiratory distress syndrome (ARDS). The grant, awarded May 15,...
- Federal Project Grant Award Summary Duke University's Office of Research Administration has received a $1,364,077 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025 through June 30, 2030. The award funds the REPAIR-ARDS (Resilience Endotype-Derivation Through Parsimonious Analysis and Causal Inference of Recovery from Acute Respiratory Distress Syndrome) initiative, which...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $744,880 to the University of Colorado-Denver through the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a four-year research project running from September 1, 2025, through May 31, 2029. The research investigates epimetabolic regulation of macrophage activation during acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), focusing on how lactate produced by...
Rutgers The State University of New Jersey, Robert Wood Johnson Health Sciences (RBHS)-School of Nursing received a $554,766 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026 through March 31, 2031. The grant supports research investigating the mechanisms underlying susceptibility to ozone-induced acute respiratory distress syndrome (ARDS), a severe form of acute lung injury. The research examines how ozone exposure impairs macrophage clearance of activated neutrophils in the lungs and explores the role of surfactant protein D (SP-D) genetic polymorphisms in exacerbating inflammatory responses during sepsis-related complications. The project will deliver peer-reviewed research findings on the pathologic mechanisms linking air pollutant exposure to ARDS development, with particular focus on how specific genetic variants in the SP-D gene influence macrophage efferocytosis and neutrophil accumulation in pulmonary tissue. Research outputs will advance understanding of genetic predispositions contributing to ARDS in septic patients and may inform future therapeutic interventions targeting the identified molecular pathways. The work will be conducted at Rutgers' Newark, New Jersey location and builds upon preliminary human ozone exposure studies demonstrating relationships between ozone exposure and receptor cleavage in individuals carrying specific SP-D polymorphisms.Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $554.8k | 5/29/26 |